Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Role of Positron Emission Tomography-Computed Tomography in Locally Advanced Breast Cancer.

Garg PK, Deo SV, Kumar R.

Indian J Surg Oncol. 2015 Dec;6(4):420-6. doi: 10.1007/s13193-015-0437-5. Epub 2015 Jul 2. Review.

PMID:
27065668
2.

Molecular Imaging of Biomarkers in Breast Cancer.

Ulaner GA, Riedl CC, Dickler MN, Jhaveri K, Pandit-Taskar N, Weber W.

J Nucl Med. 2016 Feb;57 Suppl 1:53S-9S. doi: 10.2967/jnumed.115.157909. Review.

3.

Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancer.

Simoncic U, Perlman S, Liu G, Jeraj R.

Nucl Med Commun. 2015 Dec;36(12):1174-80. doi: 10.1097/MNM.0000000000000383.

PMID:
26378490
4.

Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.

Hogan MP, Goldman DA, Dashevsky B, Riedl CC, Gönen M, Osborne JR, Jochelson M, Hudis C, Morrow M, Ulaner GA.

J Nucl Med. 2015 Nov;56(11):1674-80. doi: 10.2967/jnumed.115.161455. Epub 2015 Aug 20.

5.

Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype.

Dashevsky BZ, Goldman DA, Parsons M, Gönen M, Corben AD, Jochelson MS, Hudis CA, Morrow M, Ulaner GA.

Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1666-73. doi: 10.1007/s00259-015-3080-z. Epub 2015 May 14.

PMID:
25971426
6.

Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring.

McGuire A, Brown JA, Kerin MJ.

Cancer Metastasis Rev. 2015 Mar;34(1):145-55. doi: 10.1007/s10555-015-9551-7. Review.

7.
8.

Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer.

Ulaner GA, Eaton A, Morris PG, Lilienstein J, Jhaveri K, Patil S, Fazio M, Larson S, Hudis CA, Jochelson MS.

Cancer Med. 2013 Oct;2(5):725-33. doi: 10.1002/cam4.119. Epub 2013 Sep 12.

9.

Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.

Groheux D, Hindié E, Delord M, Giacchetti S, Hamy AS, de Bazelaire C, de Roquancourt A, Vercellino L, Toubert ME, Merlet P, Espié M.

J Natl Cancer Inst. 2012 Dec 19;104(24):1879-87. doi: 10.1093/jnci/djs451. Epub 2012 Dec 12.

10.

A prospective study of bone tumor response assessment in metastatic breast cancer.

Hayashi N, Costelloe CM, Hamaoka T, Wei C, Niikura N, Theriault RL, Hortobagyi GN, Madewell JE, Ueno NT.

Clin Breast Cancer. 2013 Feb;13(1):24-30. doi: 10.1016/j.clbc.2012.09.004. Epub 2012 Oct 24.

11.

Growth in the use of PET for six cancer types after coverage by medicare: additive or replacement?

Hillner BE, Tosteson AN, Song Y, Tosteson TD, Onega T, Goodman DC, Siegel BA.

J Am Coll Radiol. 2012 Jan;9(1):33-41. doi: 10.1016/j.jacr.2011.06.019.

12.

FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer.

Niikura N, Costelloe CM, Madewell JE, Hayashi N, Yu TK, Liu J, Palla SL, Tokuda Y, Theriault RL, Hortobagyi GN, Ueno NT.

Oncologist. 2011;16(8):1111-9. doi: 10.1634/theoncologist.2011-0089. Epub 2011 Jul 17.

13.

PET/CT and breast cancer.

Hegarty C, Collins CD.

Cancer Imaging. 2010 Oct 4;10 Spec no A:S59-62. doi: 10.1102/1470-7330.2010.9031. Review.

Items per page

Supplemental Content

Write to the Help Desk